Your characterization is so on target...in the min

Your characterization is so on target...in the mind of the collective FDA...bigger is better...and largely that would be true...a bigger universe of data should provide a better estimate of what average looks like...but smaller trials with above-average results should be seen as a gateway/gaslight on results and should be considered... as you've noted, especially in the pandemic world...we currently find ourselves.